Pharmabiz

ViiV Healthcare’s long-acting Cabenuva for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges

ViiV Healthcare’s long-acting Cabenuva for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges: London, UK Friday, February 20 ...
FiercePharma

GSK’s long-acting HIV med Cabenuva beats daily therapy in patients who've faced adherence hurdles

GSK’s long-acting HIV regimen Cabenuva has already shown it works as well as daily oral therapies in patients who have the virus under control. Now, the injection has beaten daily drugs in individuals ...
Nasdaq

ViiV Healthcare Announces US FDA Approval of Cabenuva (cabotegravir, rilpivirine) for Use Every Two Months, Expanding the Label of the First and Only Complete Long-Acting HIV ...

Cabenuva is now approved for administration as few as six times a year for virologically suppressed adults living with HIV without prior treatment failure or resistance to cabotegravir or rilpivirine ...
Nasdaq

ViiV Healthcare Announces Interim Data at CROI Indicating Superior Efficacy of Long-Acting Injectable HIV Treatment Cabenuva (Cabotegravir + Rilpivirine) Compared to Daily Oral ...

LONDON--(BUSINESS WIRE)-- ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced data from a planned interim ...
MedPage Today

Monthly ART Injections Top Pills for HIV Patients With Adherence Problems

Long-acting cabotegravir/rilpivirine (Cabenuva; CAB/RPV-LA) appeared superior to daily oral antiretroviral therapy (ART) in maintaining viral load suppression for ...
Yahoo

GSK's injectable HIV drug shows promise over daily pills

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: FILE PHOTO: Illustration shows GSK (GlaxoSmithKline) logo (Reuters) - British drugmaker GSK said on Wednesday its long ...
The Inlander

FDA approves twice-yearly injection that prevents HIV, thanks in part to research by a Spokane doctor

A few weeks ago, Grant Ogren and Rhea Ashby-Durall, the executive director and the outreach manager of SAN (formerly Spokane AIDS Network), met with their representative from Gilead Sciences, the ...
AOL

GSK says within weeks of resubmitting HIV injection Cabenuva

FRANKFURT (Reuters) - GlaxoSmithKline's HIV business ViiV is within weeks of resubmitting its request for approval of its long-acting injection Cabenuva to U.S. drug regulators, ViiV's head of ...
Benzinga.com

Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data Shows

ViiV Healthcare, majority owned by GSK Plc (NYSE:GSK), with Pfizer Inc (NYSE:PFE) and Shionogi Limited as shareholders, revealed data from a planned interim analysis of the LATITUDE phase 3 trial. The ...
Medscape

Every-Other-Month Injectable HIV Treatment Works

BOSTON — HIV can be suppressed when the long-acting combination of cabotegravir plus rilpivirine (Cabenuva, ViiV Healthcare) is administered every 8 weeks, according to data from the ATLAS-2M study, ...
Medscape

Long-Acting Antiretrovirals for HIV Improve Adherence

Long-acting injectable antiretroviral treatment can improve medication adherence in patients who struggle with regularly taking daily pills, according to research presented at the Association of ...

ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,* today announced final data from the LATITUDE phase III trial, confirming its ...